Antifragile therapy
West, J.; Strobl, M.; Armagost, C.; Miles, R.; Marusyk, A.; Anderson, A. R. A.
Show abstract
Antifragility is a recently coined word used to describe the opposite of fragility. Systems or organisms can be described as antifragile if they derive a benefit from systemic variability, volatility, randomness, or disorder. Herein, we introduce a mathematical framework to quantify the fragility or antifragility of cancer cell lines in response to treatment variability. This framework enables straightforward prediction of the optimal dose treatment schedule for a range of treatment schedules with identical cumulative dose. We apply this framework to non-small-cell lung cancer cell lines with evolved resistance to ten anti-cancer drugs. We show the utility of this antifragile framework when applied to 1) treatment resistance, and 2) collateral sensitivity of sequential monotherapies.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Design principles of collateral sensitivity-based dosing strategies 94%
- Linear reinforcement learning: Flexible reuse of computation in planning, grid fields, and cognitive control 94%
- Trade-off between reducing mutational accumulation and increasing commitment to differentiation determines tissue organization 93%
Similar papers in this journal
- Predicting Anti-Cancer Drug Combination Responses with a Temporal Cell State Network Model 97%
- A model for the intrinsic limit of cancer therapy: duality of treatment-induced cell death and treatment-induced stemness 95%
- Diverse mutant selection windows shape spatialheterogeneity in evolving populations 94%
Similar papers in this journal
- Standing Variations Modeling Captures Inter-Individual Heterogeneity in a Deterministic Model of Prostate Cancer Response to Combination Therapy 93%
- Divergent resistance mechanisms to immunotherapy explains response in different skin cancers. 93%
- Computational modeling of drug response identifies mutant-specific constraints for dosing panRAF and MEK inhibitors in melanoma 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.